In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Proteins, Oligonucleotides, Nucleic Acid Probes) Technology (Immunoassay, Biochemistry, Molecular Diagnostic, Microbiology, Hematology) Use (Clinical, RUO) End User - Global Forecast to 2030

In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Proteins, Oligonucleotides, Nucleic Acid Probes) Technology (Immunoassay, Biochemistry, Molecular Diagnostic, Microbiology, Hematology) Use (Clinical, RUO) End User - Global Forecast to 2030

The global in-vitro diagnostics reagents market is projected to reach $75.67 billion by 2030, at a CAGR of 5.4% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the increasing prevalence of infectious diseases, increasing funding for research activities, the rising adoption of advanced diagnostic technologies, the growth in proteomics and genomics research studies, and the growing number of clinical laboratories offering advanced diagnostic testing menus. Additionally, emerging economies and the growing demand for protein therapeutics and personalized medicines are expected to offer significant market growth opportunities.

However, the stringent regulations for antigen-specific reagents restrain the growth of this market. Additionally, the high costs of reagents and the unfavorable reimbursement scenario pose a significant challenge to the market's growth.

Based on type, the IVD reagents market is segmented into antibodies, purified proteins and peptides, oligonucleotides, nucleic acid probes, and other reagents. In 2023, the antibodies segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the increasing R&D funding. For instance, According to Research America, investments in medical and health R&D by the U.S. has increased by 7.0% between 2019 and 2020. In 2020, the total medical and health R&D expenditure was USD 245.1 billion. Furthermore, the huge demand for antibodies in various biomedical & basic research are the factors contributing to the largest share of this segment.

Based on technology, the IVD reagents market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies. In 2023, the immunoassay/immunochemistry segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the increasing use of immunoassays in infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests. Further, the coronavirus (COVID-19) outbreak since December 2019 is expected to accelerate the growth of this segment owing to the national emergency declared and the requirement of various reagents for the kits and assay preparation.

Based on the use, the IVD reagents market is segmented into clinical use, research use only (RUO), and analyte-specific reagents (ASR). In 2023, the clinical use segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the growing need for the early detection of various epidemic and pandemic infections, the large volume of test samples diagnosed for clinical purposes, and initiatives undertaken by manufacturers to develop advanced IVD reagents drive the demand for IVD reagents for clinical use.

Based on the end user, the IVD reagents market is segmented into IVD manufacturers, reference laboratories, academic institutes and research laboratories, and hospital laboratories. In 2023, the IVD manufacturers segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the initiatives undertaken by IVD manufacturers and the increasing demand for pharmaceutical & biopharmaceutical products from emerging countries.

An in-depth analysis of the geographic scenario of IVD reagents provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the IVD reagents market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Furthermore, in 2023, the U.S. is expected to account for the largest share of the IVD reagents market in North America. The market growth in the U.S. is attributed to the increasing prevalence of infectious diseases, growing preference for PoC testing and personalized medicine, and rising funds and investments for research reagents.

Some of the key players operating in the IVD reagents market report are Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), Bio Techne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.).

Scope of the Report:

IVD Reagents Market Size & Trend Analysis—by Type

Antibodies
Antibodies Market, By Type
Monoclonal Antibodies
Polyclonal Antibodies
Antibodies Market, By Target
Cluster of Differentiation (CD)
T-cell Receptor (TCR)
Epidermal Growth Factor Receptor (EGFR)
Other Targets
Purified Proteins and Peptides
Oligonucleotides
Nucleic Acid Probes
Other Reagents

Notes: 1. Other targets include Nucleic BCMA, DLL/Notch, EpCAM, HER2, PDGFRα, Claudin 18.2, SLAMF7, and DKK1. B-cell maturation antigen (BCMA).
2. Other reagents include blocking agents, detergents, surfactants, wetting agents, buffers, stabilizers, purified water, dyes, standards and controls, enzymes, cell culture reagents, and anti-coagulants.

IVD Reagents Market Size & Trend Analysis—by Technology

Immunoassay/Immunochemistry
Enzyme-linked Immunosorbent Assays (ELISA) and Enzyme-linked Immunospot Assays (ELISpot)
Lateral Flow Assays (LFA)/Rapid Tests
Western Blotting (WB)
Immunofluorescence (IF)
Functional Assays
Immunoprecipitation (IP)
Other Immunoassay Technologies
Biochemistry/Clinical Chemistry
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Hybridization
Isothermal Nucleic Acid Amplification Technology
DNA Sequencing & Next-generation Sequencing
Microarray
Other Molecular Diagnostic Technologies
Microbiology
Hematology
Coagulation/Hemostasis
Urinalysis
Other IVD Technologies

Note: 1. Other technologies include virus neutralization tests, agar gel immunodiffusion, and radioimmunoassay.
2. Other molecular diagnostic technologies include electrophoresis, ligase chain reaction (LCR), northern blot, and southern blot.
3. Other IVD technologies include anatomical pathology, histochemistry, and whole blood glucose monitoring.

IVD Reagents Market Size & Trend Analysis—by Use

Clinical Use
Research Use Only (RUO)
Analyte-specific Reagents (ASR)

IVD Reagents Market Size & Trend Analysis—by End User

Reference Laboratories
IVD Manufacturers
Academic Institutes and Research Laboratories
Hospital Laboratories

IVD Reagents Market Size & Trend Analysis—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Switzerland
Netherlands
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Singapore
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa

In Vitro Diagnostic (IVD) Reagents Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	389
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Type, Technology, Use, and End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), Bio-Techne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.).

FAQs About the ReportWhat is the focus of the IVD reagents market study?

This study offers a detailed assessment of the IVD reagents market and analyzes the market sizes & forecasts based on type, technology, use, and end user. This report also involves the value analysis of various segments and subsegments of the IVD reagents market at the regional and country levels.

What is the revenue generated from the sales of IVD reagents products across the globe? At what rate is their demand expected to grow for the next 5–7 years?

The IVD reagents market is projected to reach $75.67 billion by 2030, at a CAGR of 5.4% during the forecast period.

Among the types, which IVD reagents segment is expected to hold the largest share of the market in 2023?

Among the types, in 2023, the antibodies segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the advantages offered by the segment, like the inherent specificity, high throughput, high sensitivity, and low cost are driving the growth of this technology segment. Further, the increasing use of immunoassays in POC & infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests are the factors contributing to the largest share of this segment.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the IVD reagents market?

The growth of this market is driven by the increasing prevalence of infectious diseases, increasing funding for research activities, the rising adoption of advanced diagnostic technologies, the growth in proteomics and genomics research studies, and the growing number of clinical laboratories offering advanced diagnostic testing menus. Additionally, emerging economies and the growing demand for protein therapeutics and personalized medicines are expected to offer significant market growth opportunities.

Who are the major players operating in the IVD reagents market?

The key players profiled in the IVD reagents market report are Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), Bio Techne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the market players operating in the IVD reagents market?

Emerging economies, such as China and India, are expected to provide significant growth opportunities for market players due to the increasing government R&D spending in these countries.